Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study

Young, J; Scherrer, Anne Paule Marie; Günthard, H F; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C A; Cavassini, M; Bernasconi, Enos; Vernazza, P; Hirschel, Bernard; Battegay, M; Bucher, H C

doi:10.1111/j.1468-1293.2010.00885.x

Scientific article

English

Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study

ContributorsYoung, J; Scherrer, Anne Paule Marie; Günthard, H F; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C A; Cavassini, M; Bernasconi, Enos; Vernazza, P; Hirschel, Bernard; Battegay, M; Bucher, H C

Published inHIV medicine, vol. 12, no. 5, p. 299-307

Publication date2011

Abstract

Darunavir was designed for activity against HIV resistant to other protease inhibitors (PIs). We assessed the efficacy, tolerability and risk factors for virological failure of darunavir for treatment-experienced patients seen in clinical practice.

Keywords

Bayes Theorem
CD4 Lymphocyte Count
Cohort Studies
Drug Resistance, Viral
Female
HIV Infections/drug therapy/immunology
HIV Protease Inhibitors/therapeutic use
HIV-1/drug effects
Humans
Male
Middle Aged
Prospective Studies
Risk Factors
Salvage Therapy
Sulfonamides/therapeutic use
Treatment Outcome
Viral Load

Affiliation entities

Research groups

Citation (ISO format)

YOUNG, J et al. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. In: HIV medicine, 2011, vol. 12, n° 5, p. 299–307. doi: 10.1111/j.1468-1293.2010.00885.x

Article (Published version)

Identifiers

PID : unige:25125
DOI : 10.1111/j.1468-1293.2010.00885.x
PMID : 20955357

Journal ISSN1464-2662

636views

0downloads

Creation10/25/2012 11:18:00 AM

First validation10/25/2012 11:18:00 AM

Update time03/14/2023 7:54:18 PM

Status update03/14/2023 7:54:18 PM

Last indexation10/30/2024 8:16:34 AM

Archive ouverte UNIGE

Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study

Darunavir was designed for activity against HIV resistant to other protease inhibitors (PIs). We assessed the efficacy, tolerability and risk factors for virological failure of darunavir for treatment-experienced patients seen in clinical practice.

Technical informations